To determine if the PR-PPD inhibits the growth of TKI-resistant lung cancer cells, we tested whether the combination treatment of the BR2 containing PR-PPD peptide (BR2-2xPPD) and TKIs could be more effective than TKIs alone in inhibiting lung cancer cell proliferation. Here, PGR is linked to lung carcinoma.